Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Am J Health Syst Pharm ; 79(Suppl 3): S65-S73, 2022 08 19.
Article in English | MEDLINE | ID: covidwho-1860804


PURPOSE: Gabapentin is a widely prescribed analgesic with increased popularity over recent years. Previous studies have characterized use of gabapentin in the outpatient setting, but minimal data exist for its initiation in the inpatient setting. The objective of this study was to characterize the prescribing patterns of gabapentin when it was initiated in the inpatient setting. METHODS: This was a retrospective cohort study of a random sample of adult patients who received new-start gabapentin during hospital admission. Patients for whom gabapentin was prescribed as a home medication, with one-time, on-call, or as-needed orders, or who died during hospital admission were excluded. The primary outcome was characterization of the gabapentin indication; secondary outcomes included the starting and discharge doses, the number of dose titrations, the rate of concomitant opioid prescribing, and pain clinic follow-up. Patients were stratified by surgical vs nonsurgical status. RESULTS: A total of 464 patients were included, 283 (61.0%) of whom were surgical and 181 (39.0%) of whom were nonsurgical. The cohort was 60% male with a mean (SD) age of 56 (18) years; surgical patients were younger and included more women. The most common indications for surgical patients were multimodal analgesia (161; 56.9%), postoperative pain (53; 18.7%), and neuropathic pain (26; 9.2%), while those for nonsurgical patients were neuropathic pain (72; 39.8%) and multimodal analgesia (53; 29.3%). The mean starting dose was similar between the subgroups (613 mg for surgical patients vs 560 mg for nonsurgical patients; P = 0.196). A total of 51.6% vs 81.8% of patients received gabapentin at discharge (P < 0.0001), while referral/follow-up to a pain clinic was minimal and similar between the subgroups (1.1% vs 3.9%; P = 0.210). CONCLUSION: Inpatients were commonly initiated on gabapentin for generalized indications, with approximately half discharged on gabapentin. Further studies are needed to assess the impact of this prescribing on chronic utilization.

Analgesics, Opioid , Neuralgia , Adult , Analgesics, Opioid/therapeutic use , Female , Gabapentin/therapeutic use , Humans , Inpatients , Male , Middle Aged , Neuralgia/drug therapy , Pain, Postoperative/drug therapy , Practice Patterns, Physicians' , Retrospective Studies
Brachytherapy ; 20(1): 284-289, 2021.
Article in English | MEDLINE | ID: covidwho-695371


PURPOSE: The COVID-19 pandemic presents serious challenges for brachytherapists, and in the time-sensitive case of locally advanced cervical cancer, the need for curative brachytherapy (BT) is critical for survival. Given the high-volume of locally advanced cervical cancer in our safety-net hospital, we developed a strategy in close collaboration with our gynecology oncology and anesthesia colleagues to allow for completely clinic-based intracavitary brachytherapy (ICBT). METHODS AND MATERIALS: This technical report will highlight our experience with the use of paracervical blocks (PCBs) and oral multimodal analgesia (MMA) for appropriately selected cervical ICBT cases, allowing for completely clinic-based treatment. RESULTS: 18 of 19 (95%) screened patients were eligible for in-clinic ICBT. The excluded patient had significant vaginal fibrosis. 38 of 39 intracavitary implants were successfully transitioned for entirely in-clinic treatment utilizing PCBs and oral MMA (97% success rate). One case was aborted due to inadequate analgesia secondary to a significantly delayed case start time (PO medication effect diminished). 95% of patients reported no pain at the conclusion of the procedure. The median (IQR) D2cc for rectum and bladder were 64.8 (58.6-70.2) Gy and 84.1 (70.9-89.4) Gy, respectively. Median (IQR) CTV high-risk D90 was 88.0 (85.6-89.8) Gy. CONCLUSIONS: In a multidisciplinary effort, we have successfully transitioned many ICBT cases to the clinic with the use of PCB local anesthesia and oral multimodality therapy in direct response to the current pandemic, thereby mitigating exposure risk to patients and staff as well as reducing overall health care burden.

Ambulatory Surgical Procedures/methods , Analgesics/therapeutic use , Anesthesia, Local/methods , Anesthesia, Obstetrical/methods , Brachytherapy/methods , Pain, Procedural/prevention & control , Uterine Cervical Neoplasms/radiotherapy , Anti-Anxiety Agents/therapeutic use , Antiemetics/therapeutic use , COVID-19 , Female , Gabapentin/therapeutic use , Humans , Hydromorphone/therapeutic use , Ibuprofen/therapeutic use , Lorazepam/therapeutic use , Organs at Risk , Pain, Procedural/drug therapy , Pandemics , Promethazine/therapeutic use , Radiotherapy Dosage , Rectum , SARS-CoV-2 , Urinary Bladder , Uterine Cervical Neoplasms/pathology